Can you provide a comprehensive overview of aortic stenosis, including its pathophysiology, clinical presentation, diagnosis, and management?

Comprehensive Overview of Aortic Stenosis

Epidemiology and Pathophysiology

Aortic stenosis (AS) is the most common non-rheumatic valvular heart disease, affecting 2-5% of adults over 65 years and approximately 12% of those over 75 years, leading to more than 100,000 deaths annually worldwide. 1, 2

• The disease is characterized by progressive calcification and fibrosis of either a congenital bicuspid or normal trileaflet aortic valve, initiated by lipid infiltration and inflammation 2
• AS represents an indolent disease with years to decades of slow progression followed by rapid clinical deterioration once symptoms develop 3
• Once aortic velocity exceeds 2 m/s, progression to severe AS typically occurs within 10 years 2

Clinical Presentation and Natural History

The development of symptoms in severe AS is associated with a 1-year mortality rate of up to 50% without valve replacement, making symptom recognition critical. 2

Classic Symptom Triad:

• Exertional dyspnea and exercise intolerance - reflecting heart failure 2
• Angina - due to increased myocardial oxygen demand from left ventricular hypertrophy 2
• Syncope - from inadequate cardiac output during exertion 2

Compensatory Mechanisms:

• During the asymptomatic latent period, left ventricular hypertrophy and atrial augmentation of preload compensate for increased afterload 4
• As disease worsens, these mechanisms become inadequate, leading to symptom onset 4
• Early AS stages (A and B) are already associated with greater left ventricular wall thickness, mass, and elevated filling pressures 5

Diagnostic Evaluation

Echocardiographic Criteria for Severe AS:

Severe AS is definitively diagnosed when any of the following criteria are met: 2

• Aortic velocity ≥4 m/s
• Mean gradient ≥40 mmHg
• Valve area ≤1.0 cm²

Initial Workup:

• Transthoracic echocardiography is the diagnostic test of choice 6
• Electrocardiogram (typically shows left ventricular hypertrophy) 6
• Complete blood count, basic metabolic profile, coagulation studies 6
• Troponin and brain natriuretic peptide levels 6
• Chest radiograph 6
• Point-of-care ultrasound has demonstrated good accuracy when formal echocardiography is not immediately feasible 6

Special Diagnostic Considerations:

Low-Flow Low-Gradient AS:

• Guidelines recommend valve replacement for symptoms and/or impaired LV systolic function with evidence of flow reserve during low-dose dobutamine stress echocardiography 7
• Projected valve area at normal flow rate provides additional diagnostic and prognostic information on par with resting transvalvular flow rate 7

Exercise Testing in Asymptomatic Patients:

• When symptom status is unclear (particularly in elderly patients with comorbidities or mobility impairment), exercise testing/exercise stress echo becomes an important decision-making element 7
• Serum BNP and predictors of rapid progression (rapid change in peak jet velocity, disproportionate LV hypertrophy, severe valve calcification) guide management 7

Management Strategy

Asymptomatic Severe AS

The 2025 ESC/EACTS guidelines mark a paradigm shift toward earlier intervention in many asymptomatic patients with severe AS, challenging the traditional symptom-driven watchful waiting approach. 8

Indications for Intervention in Asymptomatic Patients:

Definite Indications (Class I):

• Left ventricular ejection fraction <55% (ESC/EACTS) or <60% over serial imaging (ACC/AHA) 1
• Very severe AS (AVA ≤0.75 cm² with peak velocity ≥4.5 m/s or mean gradient ≥50 mmHg) based on RECOVERY trial data showing lower operative mortality and cardiovascular death at 6 years with early intervention 7

Additional Considerations:

• High-risk profession (airline pilot) or lifestyle (competitive athlete) 7
• Anticipated inaccessibility of close medical supervision 7
• Presence of both left ventricular and left atrial extra-aortic valve abnormalities (associated with 1.7-fold greater likelihood of AS progression) 5

Surveillance Intervals for Conservative Management:

• Severe AS: Every 6-12 months 2, 4
• Moderate AS: Every 1-2 years 2, 4
• Mild AS: Every 3-5 years 2, 4

Symptomatic Severe AS

Aortic valve replacement is definitively recommended for all symptomatic patients with severe AS, as it restores average life expectancy comparable to age-matched controls. 2

• In patients over 70 years with low surgical risk, 10-year all-cause mortality was 62.7% with TAVI and 64.0% with SAVR, demonstrating equivalence 2
• Symptomatic patients require prompt treatment, as survival decreases rapidly after symptom onset 2

Moderate AS with Heart Failure

Current guidelines do not recommend AVR for moderate AS at rest or on low-dose dobutamine stress echo, though this remains an area of active investigation. 7

• There is excess mortality associated with moderate AS during long-term follow-up, with increased risk threshold at mean gradient of 20 mmHg and peak velocity of 3 m/s 7
• The ongoing TAVI UNLOAD trial (NCT02661451) is randomizing 600 patients with moderate AS and HFrEF to evaluate whether early TAVI reduces readmissions and improves outcomes 7

Choice of Intervention: TAVI vs SAVR

Age-Based Recommendations

2020 ACC/AHA Guidelines: 2

• ≤65 years: SAVR recommended
• 66-79 years: SAVR or TAVI (shared decision-making)
• ≥80 years or surgical mortality ≥8%: TAVI recommended

2021 ESC/EACTS Guidelines: 1

• ≥65 years: Threshold for surgical bioprosthesis consideration
• Multiple patient factors and preferences incorporated beyond age alone

Key Differences Between TAVI and SAVR:

TAVI Advantages: 2

• Decreased length of hospitalization
• More rapid return to normal activities
• Less procedural pain

SAVR Advantages: 9

• Proven long-term durability (especially important for younger patients)
• Lower rates of conduction disturbances
• Greater procedural flexibility for lifetime management
• Better outcomes with bicuspid valves and anatomical challenges

Critical Caveat: Evidence supporting TAVI for patients younger than 65 years and long-term outcomes beyond 5 years are less well defined than for SAVR 2, 9

Heart Team Approach

Both ESC/EACTS and ACC/AHA provide Class I/COR I, Level of Evidence C recommendations for multidisciplinary Heart Team evaluation. 1

• The Heart Team takes a multidisciplinary appraisal of patient and procedural factors to devise optimal treatment strategy 1
• Risk stratification for TAVI vs SAVR is now mainly based on predicted life expectancy rather than surgical risk scores alone 1
• High-volume centers are associated with better outcomes, though neither guideline specifies minimum case volumes 1

Acute Management Considerations

Hemodynamic Management in the Emergency Setting:

Preload Restoration: 6

• Restoring preload is critical as AS patients are preload-dependent
• Avoid hypovolemia which can lead to rapid decompensation

Heart Rate Management: 6

• Maintain normal heart rate - both bradycardia and tachycardia lead to clinical decompensation
• Bradycardia reduces cardiac output; tachycardia reduces diastolic filling time

Blood Pressure Management: 6

• For hypertensive patients with heart failure symptoms, nitrate agents may be reasonable but hypotension must be avoided
• For hypotensive patients, vasopressors should be used at the lowest effective dose
• Dobutamine can increase inotropy when needed

Temporizing Measures: 6

• Extracorporeal membrane oxygenation and percutaneous balloon dilatation have been described as bridge therapies to definitive valve replacement

Medical Management

No medical therapies have proven effective in halting or reversing AS progression. 3

• Treatment of concurrent hypertension, atrial fibrillation, and coronary artery disease optimizes outcomes 4
• Management of hyperlipidemia and smoking cessation are indicated as part of cardiovascular risk reduction 2
• Patient education about prompt symptom reporting is essential 4

Cardiology Referral Indications

Immediate cardiology referral is recommended for: 4

• All patients with symptomatic moderate or severe AS
• Patients with severe AS without apparent symptoms
• Patients with left ventricular systolic dysfunction

Contemporary Trends and Future Directions

The proactive management model advocated by international experts includes: 8

• Early referral to multidisciplinary Heart Valve Team
• Streamlined evaluation with upstream testing
• Prompt aortic valve replacement in many asymptomatic patients
• More urgent treatment for symptomatic patients
• Structured surveillance with close collaboration between referring clinician and Heart Valve Team when intervention is deferred

Areas of Ongoing Investigation: 7, 1

• TAVI in asymptomatic patients (ongoing trials)
• Appropriateness of Ross procedures
• Concomitant coronary revascularization with AVR
• Management of bicuspid AS
• Optimal timing of intervention in moderate AS with heart failure

Key Divergences Between Guidelines: 1

• LVEF threshold for intervention (55% ESC vs 60% ACC/AHA)
• Age thresholds for bioprosthetic vs mechanical valves
• Specific age cut-offs for TAVI vs SAVR despite limited evidence